2025 ICD-10-CM Procedure Code XW0433A

Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10

ICD-10-PCS Code:: XW0433A
ICD-10-PCS Code for:: Introduce Bentracimab in Central Vein, Perc, New Tech 10
Is Billable?: Yes - Valid for Submission
Code Navigator:

XW0433A is a billable procedure code used to specify the performance of introduction of bentracimab, ticagrelor reversal agent into central vein, percutaneous approach, new technology group 10. The code is valid for the year 2025 for the submission of HIPAA-covered transactions. The procedure code involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Table of Contents

Code Information
PCS Table
Replacement Code
Other Similar Codes

XW0433A PCS Table

In an PCS table each code is represented by up seven alphanumeric characters, with each character in the table respresenting different aspects of the procedure. In the table provided below, each row represents an individual character and includes information about the character's position, designation, label, and procedure notes. For this PCS table the procedure code is in the new technology section and is part of the anatomical regions body system, classified under introduction operation. The applicable bodypart for this procedure code is central vein.

Position	Designation	Character	Label	Procedures Notes
1	Section	X	New Technology
2	Body System	W	Anatomical Regions
3	Operation	0	Introduction	Involves: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
4	BodyPart	4	Central Vein
5	Approach	3	Percutaneous	Involves: Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
6	Device/Substance/Technology	3	Bentracimab, Ticagrelor Reversal Agent
7	Qualifier	A	New Technology Group 10

New 2025 ICD-10-PCS Code

XW0433A is new to ICD-10-PCS code set for the FY 2025, effective October 1, 2022.

Replacement Code

XW0433A replaces the following previously assigned ICD-10-PCS code(s):

3E043GC - Introduce Oth Therap Subst in Central Vein, Perc
3E043GC - Introduce Oth Therap Subst in Central Vein, Perc
3E043GC - Introduce Oth Therap Subst in Central Vein, Perc
3E043GC - Introduce Oth Therap Subst in Central Vein, Perc
3E043GC - Introduce Oth Therap Subst in Central Vein, Perc
3E043GC - Introduce Oth Therap Subst in Central Vein, Perc

Other ICD-10-PCS Codes Used for Introduction Central Vein

Filter related codes list:

XW04306 Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6
XW04308 Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
XW04326 Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6
XW04336 Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
XW0434A Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
XW04357 Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW04358 Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
XW0435A Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
XW04366 Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW04367 Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
XW04368 Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
XW04372 Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
XW04377 Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
XW04378 Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
XW04387 Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
XW04388 Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
XW0438A Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10
XW04396 Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW04398 Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
XW0439A Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
XW043A6 Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
XW043B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
XW043B6 Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043B7 Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW043BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10
XW043C6 Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6
XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043CA Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
XW043D6 Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
XW043E5 Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043E6 Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043F3 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
XW043F5 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
XW043F6 Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10
XW043G5 Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043G6 Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043H5 Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043H6 Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043K9 Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
XW043L6 Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
XW043L7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043P9 Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
XW043Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
XW043Q9 Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
XW043R9 Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9
XW043S5 Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
XW043W5 Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5

What is ICD-10-PCS?

The ICD-10 Procedure Coding System (ICD-10-PCS) is a catalog of procedural codes used by medical professionals for hospital inpatient healthcare settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates. The 2025 ICD-10-PCS codes are to be used for discharges occurring from October 1, 2024 through September 30, 2025.

Each ICD-10-PCS code has a structure of seven alphanumeric characters and contains no decimals. The first character defines the major "section". Depending on the "section" the second through seventh characters mean different things.